AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Dia etf rebalance12/29/2023 ![]() ![]() "In our first year, assets under management have grown to more than $50 million," stated Andrew McDonald, Ph.D., CEO of LifeSci Index Partners. The BioShares funds are also celebrating their one-year anniversary, as they share the inception date of December 16, 2014. "The balance sheets of the BBC stocks are strong" said Yook, "with more than $20 billion of cash across the 89 portfolio companies, and the BBP components offers strong revenue growth opportunity with median sales growth of 23% projected in 2016 according to Bloomberg estimates." "In the BBC clinical trials fund, 9 companies with IPOs in 2015 have been added, with exciting clinical trials in areas such as peanut allergy, Alzheimer's, sickle cell anemia and various approaches to cancer treatment." In addition, a handful of companies experienced clinical trial failures and the rules-driven BioShares portfolios reacted by culling these holdings. "Our rules-driven BioShares portfolios continue to evolve in response to recent market volatility and the dynamic activity in the biotechnology capital markets," said LifeSci Index Partners founder Paul Yook. Of particular note, there were no stocks that transitioned from the Clinical stage to the Products stage during this six-month period. The BBP fund has decreased its number of holdings to 35 stocks (previously 38), with a weighted average market cap of $18 billion (previously $18 billion). 15 stocks have been removed as they no longer meet the fund's inclusion criteria, and one stock has been removed after signing a definitive merger agreement. 16 stocks have been added by meeting the inclusion criteria. The BBC fund continues to hold 89 stocks, with a weighted average market capitalization of $1.2 billion (previously $1.3 billion). In addition, BBC and BBP are the only ETFs to offer pure biotechnology exposure without allocations to specialty pharmaceutical, medical device and diagnostics, and generic drug companies. ![]() The BioShares Biotechnology Clinical Trial Fund BBC and BioShares Biotechnology Product Fund BBP offer investors exposure to these two distinct segments of the biotechnology sector while diversifying some of the risks associated with any single company. ![]() The BioShares Biotechnology Funds are the only ETFs to separate Clinical Trials stage companies and Products stage companies into two distinct funds. These passively-managed funds are designed to track their respective, rules-based indexes. 16, 2015 (GLOBE NEWSWIRE) - LifeSci Index Partners, LLC ("LSIP"), a New York City-based investment advisor and index provider, today announced the completion of its semi-annual rebalancing and recomposition for its BioShares Biotechnology exchange-traded funds (ETFs), which trade under the symbols BBC and BBP on Nasdaq. ![]()
0 Comments
Read More
Leave a Reply. |